News
Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On May 14, 2024
Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
EQS-News: MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Xencor Reports First Quarter 2024 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
“Sangamo continues to progress its
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale
Charles River Laboratories Announces First-Quarter 2024 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03
ICON releases its ICON Cares 2023 Report
ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2023 Report. This outlines how the company is delivering on its
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in
e-therapeutics plc shares now trading on JP Jenkins
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
EQS-News: Formycon reports on successful operating business and financial figures for the first quarter of 2024
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
Savara to Present at the Citizens JMP Life Sciences Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents